Alarming Trend of Antibiotic Resistance in Pseudomonas aeruginosa Isolates

被引:0
作者
El Zowalaty, Mohamed Ezzat [1 ]
机构
[1] Zagazig Univ, Fac Pharm, Dept Microbiol & Immunol, Zagazig 44519, Egypt
关键词
Pseudomonas aeruginosa; Multidrug resistance; beta-lactamases; Efflux pumps; ANTIMICROBIAL SUSCEPTIBILITY PATTERN; CYSTIC-FIBROSIS; MOLECULAR CHARACTERIZATION; RISK-FACTORS; INFECTIONS; MECHANISMS; EPIDEMIOLOGY; PREVALENCE; BLOOD; STRAINS;
D O I
暂无
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Pseudomonas aeruginosa is a concerning opportunistic pathogen frequently causing nosocomial and life-threatening infections. The present study was thus conducted to determine the prevalence of antibiotic resistance in clinical isolates of Pseudomonas aeruginosa in Zagazig, Egypt. From 250 clinical specimens, 86 isolates of P aeruginosa (34.4%) were recovered to assess the level of antimicrobial susceptibility and to determine the possible existing resistance mechanisms to commonly used antibiotics. It was found that piperacillin, meropenem, amikacin and polymyxin B were the most effective antibiotics against P. aeruginosa followed by imipenem, ticarcillin, ciprofloxacin, ceftazidime, cefipime, gentamicin and norfloxacin. P aeruginosa isolates were found to be highly resistant to all other antibiotics tested. The identified mechanisms of resistance of P aeruginosa isolates included beta-lactamase production and involvement of multiple drug resistance efflux. The present results showed that 42 (48.8%) of the clinical aeruginosa isolates were beta-lactamase producers. Efflux pump was identified in 34 (39.5%) of the isolates that effectively mediated resistance to cefotaxime, ticarcillin, azetreonam, meropenem and norfloxacin but not to streptomycin. In conclusion, antibiotic resistance in clinical isolates of P. aeruginosa could be attributed to beta-lactamase production and the activity of multiple drug resistance efflux pumps.
引用
收藏
页码:175 / 183
页数:9
相关论文
共 45 条
[11]   Characterization of Pseudomonas aeruginosa isolated from clinical and environmental samples in Minia, Egypt:: prevalence, antibiogram and resistance mechanisms [J].
Gad, Gamal F. ;
El-Domany, Ramadan A. ;
Zaki, Sahar ;
Ashour, Hossam M. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (05) :1010-1017
[12]   The peculiarities of Pseudomonas aeruginosa resistance to antibiotics and prevalence of serogroups [J].
Gailiene, Greta ;
Pavilonis, Alvydas ;
Kareiviene, Violeta .
MEDICINA-LITHUANIA, 2007, 43 (01) :36-42
[13]   Characterization of Pseudomonas aeruginosa isolates:: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999 [J].
Gales, AC ;
Jones, RN ;
Turnidge, J ;
Rennie, R ;
Ramphal, R .
CLINICAL INFECTIOUS DISEASES, 2001, 32 :S146-S155
[14]   Susceptibility patterns and cross resistances of antibiotics against Pseudomonas aeruginosa in a teaching hospital of Turkey [J].
Gençer S. ;
Ak O. ;
Benzonana N. ;
Batirel A. ;
Özer S. .
Annals of Clinical Microbiology and Antimicrobials, 1 (1)
[15]  
Gonlugur Ugur, 2003, Ann Clin Microbiol Antimicrob, V2, P5
[16]   Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment [J].
Hancock, REW ;
Speert, DP .
DRUG RESISTANCE UPDATES, 2000, 3 (04) :247-255
[17]   Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients [J].
Hogardt, M ;
Schmoldt, S ;
Götzfried, M ;
Adler, K ;
Heesemann, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (06) :1057-1061
[18]   Antibiotic resistance patterns of bacterial isolates from blood in San Francisco County, California, 1996-1999 [J].
Huang, SS ;
Labus, BJ ;
Samuel, MC ;
Wan, DRT ;
Reingold, AL .
EMERGING INFECTIOUS DISEASES, 2002, 8 (02) :195-201
[19]   Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran [J].
Japoni, A ;
Alborzi, A ;
Kalani, M ;
Nasiri, J ;
Hayati, M ;
Farshad, S .
BURNS, 2006, 32 (03) :343-347
[20]  
Kaatz Glenn W, 2002, Expert Opin Emerg Drugs, V7, P223, DOI 10.1517/14728214.7.2.223